IBD Evidence

Behandling

Samanbering av biologiskum og framkomnum terapium

Fyrsta ferðin hevur samanborandi spurningurin — hvørji lyf, ikki um lyf — meta-analytisk svar.

Uppdatert 2 min lesing 26 tilvísingar Dokumentasjonsstyrkur 5/5

Tráður endoskopiskur snara brúktur til ovur gastrointestinal og kolonic polypektomi
Gilo1969 · CC BY-SA 3.0 · Wikimedia Commons

Hvat broyttist

Í tveimum áratíðum var evidensgrunnurin lyf-móti-placebo, sum segði læknunum at biologiskar virka og einki um hvat at velja. Netverk meta-analyse hevur broytt tað við at brúka deildar samanberingar at raðfesta terapi indirekt [1][4].

Praktiska avleiðingin er at fyrsti valið nú kann verða grundað um heldur enn at vera sjálvfylgjandi, og munir millum evni á induktión móti viðlíkahald, og á virkni móti trygd, eru sýnilig.

Samanborandi virkni av avbjóðandi terapi

Klassurnar

Avbjóðandi terapi klassur í IBD
KlassuMechanismusViðmerkingar
Anti-TNFBlokkar tumor nekrose faktor alfaLongsta tíðarskeið; immunogenitet er høvuðsavmarkingin
Anti-integrinBlokkar leukocyt traffik til tarmarnarTarm-veljandi, so góðar systemiskar trygd
Anti-IL-12/23 og anti-IL-23Blokkar interleukin signalingSterk virkni og trygd profil í seinastu samanboringum
JAK inhibitorarSmá molekyl, innanhýsis signalingOral og skjótt; hjarta- og trombosis viðvaringar
S1P modulaturarSequesterar lymfocytar í lymfknútumOral; nýggjari, minni longtíðar data

Bein til mál, ikki til symptom

Tað mest avgerandi broytingin í IBD stýring er at symptom eru ein ringur proxy fyri bólk. Fólk føla seg væl við aktivum bólki og føla seg illa í remissión. Núverandi evropeisk leiðbeiningar tískil sikta eftir objektivum merkjum — fecal calprotectin, endoskopisk heilsan — heldur enn hvussu sjúklingurin sigur seg føla.

Hetta er eisini svarið til kostspurningin, sum er reist á kostsíðuni: ein inngrip, sum betrur symptom uttan at betrur objektiv merkir, hevur ikki viðgjørt sjúkuna.

Nær eitt lyf er ikki nóg mikið

Tvífaldur biologiskur ella samanblandaður smá-molekyl terapi hevur verið mettur fyri avbjóðandi sjúku [3]. Tað er framvegis ein serfrøðilig avgerð við einum avmarkaðum evidensgrunnur, og tað er har einfrøtt arbeiði, sum karakteriserar svara ymiskleika [2] er mest líklegt at broyta praksis — við at spá hvønn mekanisma at sikta eftir í einum givnum sjúklingi heldur enn at finna tað við sekventiell miseytni.

Gøta sjón av apotekshúsinum í Bautzen, Týsklandi
Fiver, der Hellseher · CC BY-SA 4.0 · Wikimedia Commons

Vanlig spurningar

Hvat biologiskt er best?
Netverk meta-analyser raðfesta tey nú [1][4], og rætta valið fer eftir sjúku staðseting, álvarleika, ekstraintestinale einkenni og tínum egna risikoyttring.
Kann eg steðga tá eg eri í remissión?
Afturhaldið hevur stóran afturfallarisik. Tað er ein avgerð at taka við tínum teymi, baserað á objektivum merkjum heldur enn hvussu tú følir.
Eru biologiskar farligar?
Tær bera veruligar risikur, serliga infektión. Óviðgjørdur bólkur hevur eisini risikur, og samanberingin er millum tveir risikur heldur enn móti null.
Hvat er calprotectin til?
Ein avføringsmarkur fyri tarmabólk. Tað er hvussu "beina til mál" veruliga verður fylgt.
Evidensin fyri hesa síðu Ein stakkur bar, sum vísir samansetingina av teimum 20 útgávunum, ið eru nevndar á hesi síðu, eftir rannsóknartypi. 24meta-analysis (24)
20 útgávur, 2015–2025. Hetta er ein aðallega observational grundarlag. Tað kann staðfesta, at ting henda saman; tað kann ikki avgera, hvør av teimum orsakar hin. Kelda: egnu tilvísingalistin á hesi síðu, niðanfyri.

Viðmerkingar

Hver einasta tilvísing niðanfyri bendir til upprunaliga peer-reviewed skjalið á PubMed ella gjøgnum DOI. Einki her er ein staðfesting fyri læknaligt ráð.

  1. Management of paediatric ulcerative colitis, part 2: Acute severe colitis-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organization Assa A, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40528309
  2. Management of paediatric ulcerative colitis, part 1: Ambulatory care-An updated evidence-based consensus guideline from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition and the European Crohn's and Colitis Organisation Wine E, Aloi M, Van Biervliet S, et al. · Journal of pediatric gastroenterology and nutrition · 2025 · Clinical guideline DOIPubMed 40677018Full text
  3. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Crohn's Disease: 2025 AGA Evidence Synthesis Singh S, Murad MH, Yuan Y, et al. · Gastroenterology · 2025 · Meta-analysis DOIPubMed 41114682Full text
  4. ACG Clinical Guideline Update: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701556
  5. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Afzali A, et al. · The American journal of gastroenterology · 2025 · Clinical guideline DOIPubMed 40701562
  6. AGA Clinical Practice Guideline on the Management of Pouchitis and Inflammatory Pouch Disorders Barnes EL, Agrawal M, Syal G, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38128971Full text
  7. AGA Clinical Practice Update on Diet and Nutritional Therapies in Patients With Inflammatory Bowel Disease: Expert Review Hashash JG, Elkins J, Lewis JD, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 38276922
  8. Comparative Efficacy of Advanced Therapies for Management of Moderate-to-Severe Ulcerative Colitis: 2024 American Gastroenterological Association Evidence Synthesis Ananthakrishnan AN, Murad MH, Scott FI, et al. · Gastroenterology · 2024 · Meta-analysis DOIPubMed 39425738Full text
  9. AGA Living Clinical Practice Guideline on Pharmacological Management of Moderate-to-Severe Ulcerative Colitis Singh S, Loftus EV Jr, Limketkai BN, et al. · Gastroenterology · 2024 · Clinical guideline DOIPubMed 39572132Full text
  10. ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment Adamina M, Minozzi S, Warusavitarne J, et al. · Journal of Crohn's & colitis · 2024 · Clinical guideline DOIPubMed 38878002
  11. Single-cell meta-analysis of inflammatory bowel disease with scIBD Nie H, Lin P, Zhang Y, et al. · Nature computational science · 2023 · Meta-analysis DOIPubMed 38177426
  12. JAK inhibitors and the risk of malignancy: a meta-analysis across disease indications Russell MD, Stovin C, Alveyn E, et al. · Annals of the rheumatic diseases · 2023 · Meta-analysis DOIPubMed 37247942Full text
  13. Altered Bioavailability and Pharmacokinetics in Crohn's Disease: Capturing Systems Parameters for PBPK to Assist with Predicting the Fate of Orally Administered Drugs Alrubia S, Mao J, Chen Y, et al. · Clinical pharmacokinetics · 2022 · Meta-analysis DOIPubMed 36056298Full text
  14. Dual Biologic or Small Molecule Therapy for Treatment of Inflammatory Bowel Disease: A Systematic Review and Meta-analysis Ahmed W, Galati J, Kumar A, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2022 · Meta-analysis DOIPubMed 33798711
  15. Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis Lasa JS, Olivera PA, Danese S, et al. · The lancet. Gastroenterology & hepatology · 2022 · Meta-analysis DOIPubMed 34856198
  16. Efficacy of Biologic Drugs in Short-Duration Versus Long-Duration Inflammatory Bowel Disease: A Systematic Review and an Individual-Patient Data Meta-Analysis of Randomized Controlled Trials Ben-Horin S, Novack L, Mao R, et al. · Gastroenterology · 2022 · Meta-analysis DOIPubMed 34757139
  17. Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis Peyrin-Biroulet L, Arkkila P, Armuzzi A, et al. · BMC gastroenterology · 2022 · Meta-analysis DOIPubMed 35676620Full text
  18. [ESPEN guideline: Clinical nutrition in inflammatory bowel disease] Bischoff SC, Escher J, Hébuterne X, et al. · Nutricion hospitalaria · 2022 · Clinical guideline DOIPubMed 35014851
  19. Long-term dietary patterns are associated with pro-inflammatory and anti-inflammatory features of the gut microbiome Bolte LA, Vich Vila A, Imhann F, et al. · Gut · 2021 · Meta-analysis DOIPubMed 33811041Full text
  20. Ulcerative Colitis-Diagnostic and Therapeutic Algorithms Kucharzik T, Koletzko S, Kannengiesser K, et al. · Deutsches Arzteblatt international · 2020 · Meta-analysis DOIPubMed 33148393Full text
  21. The association between endometriosis and autoimmune diseases: a systematic review and meta-analysis Shigesi N, Kvaskoff M, Kirtley S, et al. · Human reproduction update · 2019 · Meta-analysis DOIPubMed 31260048Full text
  22. ACG Clinical Guideline: Ulcerative Colitis in Adults Rubin DT, Ananthakrishnan AN, Siegel CA, et al. · The American journal of gastroenterology · 2019 · Clinical guideline DOIPubMed 30840605
  23. ACG Clinical Guideline: Management of Crohn's Disease in Adults Lichtenstein GR, Loftus EV, Isaacs KL, et al. · The American journal of gastroenterology · 2018 · Clinical guideline DOIPubMed 29610508
  24. Management of Paediatric Ulcerative Colitis, Part 1: Ambulatory Care-An Evidence-based Guideline From European Crohn's and Colitis Organization and European Society of Paediatric Gastroenterology, Hepatology and Nutrition Turner D, Ruemmele FM, Orlanski-Meyer E, et al. · Journal of pediatric gastroenterology and nutrition · 2018 · Clinical guideline DOIPubMed 30044357
  25. Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease de Lange KM, Moutsianas L, Lee JC, et al. · Nature genetics · 2017 · Meta-analysis DOIPubMed 28067908Full text
  26. Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations Liu JZ, van Sommeren S, Huang H, et al. · Nature genetics · 2015 · Meta-analysis DOIPubMed 26192919Full text

Henda síða varð sjálvvirkandi týdd úr enskt. Tilvísingarnar og tølini eru óbroytt. Les upprunaliga enska útgávuna um nakað lesist undarliga. Les upprunaliga enska útgávuna